Perioperative chemotherapy is entirely based on patient age, tumor size, histologic grade, lymph node metastases, hormone receptor status, and HER2 status (7), (8), and it has contributed to the decrease in breast cancer mortality recently (9). This evidence concerns the gene ERBB2 and breast carcinoma.